GB9210839D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB9210839D0
GB9210839D0 GB929210839A GB9210839A GB9210839D0 GB 9210839 D0 GB9210839 D0 GB 9210839D0 GB 929210839 A GB929210839 A GB 929210839A GB 9210839 A GB9210839 A GB 9210839A GB 9210839 D0 GB9210839 D0 GB 9210839D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929210839A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB929210839A priority Critical patent/GB9210839D0/en
Publication of GB9210839D0 publication Critical patent/GB9210839D0/en
Priority to JP5520016A priority patent/JPH07506591A/ja
Priority to CA002136196A priority patent/CA2136196A1/en
Priority to PCT/GB1993/001014 priority patent/WO1993023401A1/en
Priority to EP93910221A priority patent/EP0641344A1/en
Priority to AU40814/93A priority patent/AU4081493A/en
Priority to ZA933494A priority patent/ZA933494B/xx
Priority to CN93107586A priority patent/CN1094046A/zh
Priority to MX9302957A priority patent/MX9302957A/es
Priority to TW082104444A priority patent/TW277062B/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB929210839A 1992-05-21 1992-05-21 Novel compounds Pending GB9210839D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds
AU40814/93A AU4081493A (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
EP93910221A EP0641344A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
CA002136196A CA2136196A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
PCT/GB1993/001014 WO1993023401A1 (en) 1992-05-21 1993-05-18 8-substituted anthines as phosphodiesterase inhibitors
JP5520016A JPH07506591A (ja) 1992-05-21 1993-05-18 ホスホジエステラーゼ阻害剤としての８−置換キサンチン
ZA933494A ZA933494B (en) 1992-05-21 1993-05-19 Xanthine phosphodiesterase inhibitors
CN93107586A CN1094046A (zh) 1992-05-21 1993-05-20 取代的黄嘌呤衍生物
MX9302957A MX9302957A (es) 1992-05-21 1993-05-20 Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
TW082104444A TW277062B (enExample) 1992-05-21 1993-06-03

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB9210839D0 true GB9210839D0 (en) 1992-07-08

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929210839A Pending GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds

Country Status (10)

Country Link
EP (1) EP0641344A1 (enExample)
JP (1) JPH07506591A (enExample)
CN (1) CN1094046A (enExample)
AU (1) AU4081493A (enExample)
CA (1) CA2136196A1 (enExample)
GB (1) GB9210839D0 (enExample)
MX (1) MX9302957A (enExample)
TW (1) TW277062B (enExample)
WO (1) WO1993023401A1 (enExample)
ZA (1) ZA933494B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) * 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2000068231A1 (en) 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
NZ517546A (en) * 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1315835C (zh) 2001-08-28 2007-05-16 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
US7495004B2 (en) 2002-06-17 2009-02-24 Glaxo Group Limited Purine derivatives as liver X receptor agonists
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
MXPA06001195A (es) 2003-07-31 2006-04-11 Schering Corp Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil.
RU2007114908A (ru) 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779374D1 (en) * 1986-08-28 1992-07-02 Sandoz Ag Xanthinderivate.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
WO1992011260A1 (en) * 1990-12-21 1992-07-09 Beecham Group Plc Xanthine derivatives

Also Published As

Publication number Publication date
AU4081493A (en) 1993-12-13
MX9302957A (es) 1994-05-31
TW277062B (enExample) 1996-06-01
JPH07506591A (ja) 1995-07-20
EP0641344A1 (en) 1995-03-08
CA2136196A1 (en) 1993-11-25
WO1993023401A1 (en) 1993-11-25
CN1094046A (zh) 1994-10-26
ZA933494B (en) 1994-03-01

Similar Documents

Publication Publication Date Title
GB9210839D0 (en) Novel compounds
GB9202779D0 (en) Novel compounds
GB9203476D0 (en) Novel compounds
GB9200713D0 (en) Novel compounds
GB9204996D0 (en) Novel compounds
GB9201290D0 (en) Novel compounds
GB9201483D0 (en) Novel compounds
GB9201506D0 (en) Novel compounds
GB9201507D0 (en) Novel compounds
GB9201957D0 (en) Novel compounds
GB9201995D0 (en) Novel compounds
GB9202022D0 (en) Novel compounds
GB9202050D0 (en) Novel compounds
GB9201291D0 (en) Novel compounds
GB9202930D0 (en) Novel compounds
GB9203369D0 (en) Novel compounds
GB9203370D0 (en) Novel compounds
GB9203428D0 (en) Novel compounds
GB9203472D0 (en) Novel compounds
GB9205022D0 (en) Novel compounds
GB9203554D0 (en) Novel compounds
GB9203555D0 (en) Novel compounds
GB9203556D0 (en) Novel compounds
GB9205441D0 (en) Novel compounds
GB9205440D0 (en) Novel compounds